[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hand-osteoarthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hand-osteoarthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,70,99,121,148,169,194,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100590345","phase-3-multiprofen-cc-to-reduce-pain-in-hand-arthritis-100590345",false,"NCT06966206","Multiprofen-CC to Reduce Pain in Hand Arthritis","Multiprofen-CC to Reduce Pain in Hand Arthritis (MRP-HAND): A Crossover Randomized Controlled Trial","MRP-HAND","Inclusion Criteria:\n\n* Adults (18+)\n* Have been diagnosed with hand osteoarthritis according to American College of Rheumatology criteria\n* Experience pain and\u002For loss of function in one or both hands that interferes with daily life\n* Provide informed consent\n\nExclusion Criteria:\n\n* Unable to consent\n* Unable or unwilling to follow study protocol\n* Known allergy or contraindication to any of the study drugs or their ingredients\n* Have open wounds\u002Fcuts and\u002For skin conditions on the hand area\n* Pregnant or breastfeeding\n* History of impaired kidney or liver function\n* Rheumatoid or other inflammatory arthropathy\n* Hand surgery within the past 6 months or planned within the study period.\n* Use daily opioids (other than short acting codeine) for a chronic pain condition other than hand arthritis","ALL","18 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This clinical trial aims to find out if using 1 gram of Multiprofen-CC cream on the hands three times a day for 4 weeks can help reduce pain in adults with hand osteoarthritis, compared to a placebo (a cream with no active medicine). The research team will also look at how Multiprofen-CC affects hand function, opioid use, and how patients feel about their overall improvement. In addition, the research team will keep track of any side effects.\n\nParticipants will:\n\n* Use both Multiprofen-CC and a placebo (a cream with no active medicine) during the study, in a random order.\n* Be asked to apply 1 gram of cream to their hands three times a day for 2 weeks, following the manufacturer's instructions.\n* Attend a visit before starting the study, after 2 weeks, and after 6 weeks.\n* Report any symptoms they experience during the study.",[27],"Hand Osteoarthritis",[29,30,31,32,33],"hand osteoarthritis","osteoarthritis","arthritis","topical","multiprofen","RECRUITING","2026-04-28",{"date":37,"type":38},"2026-05-04","ACTUAL",{"date":40,"type":38},"2026-03-09",{"date":42,"type":21},"2027-08-01",{"name":44,"class":45},"St. Joseph's Healthcare Hamilton","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100621511","phase-3-the-efficacy-and-safety-of-intramuscular-methylprednisolone-in-patients-with-hand-osteoarthritis-100621511","NCT07371572","The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis","The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis - the IMHOA Trial","IMHOA","Inclusion Criteria:\n\n* Patients with interphalangeal hand OA (according to the EULAR classification criteria 2023) based on patient report (age, morning stiffness) and radiographs of ≤6 months old (osteophytes, JSN (joint space narrowing) and symptom-structure concordance (present if majority (≥50%) of the symptomatic joints demonstrate radiographic findings)).\n* Age ≥ 16 years\n* Have hand pain \\>40mm on a 100mm visual analogue scale (VAS)\n* Have previously experienced failure of at least one conventional type of pain medication, (self-reported of insufficient effect from topical or oral NSAID, etc. with exclusion of paracetamol)\n\nExclusion Criteria:\n\n* Comorbidity\n\n  * Chronic inflammatory (rheumatic) diseases\n  * Infectious diseases\n  * Known Osteoporosis\n  * Known Diabetes\n  * Previous diagnosis of fibromyalgia\n  * Known myasthenia gravis\n* Previous surgical interventions on the hand (e.g. carpal tunnel syndrome, etc.)\n* Use of other Medication: In order to maximize the generalizability of the study interactions between methylprednisolone and co-medication is only prohibited when the Dutch Medication Surveillance System (Z-index) gives a signal for this interaction.\n* Patients with a contraindication for MP\n\n  * Current Gastric and duodenal ulcers\n  * Current infections\n  * Liver cirrhosis\n  * Pregnant or breastfeeding\n  * Known non-response or intolerance for MP\n* Not able to read or write the Dutch language\n* Neurological diagnosis\n\n  * Epilepsy\n  * Risk of psychiatric disorder","16 Years",{"count":57,"type":21},212,[24],"The goal of this clinical trial is to determine the efficacy and safety of intramuscular methylprednisolone in patients with hand osteoarthritis. The main question it aims to answer is what the difference is in hand pain 4 weeks after the first injection with methylplrednisolone. This main goal will be assessed in the first 16 weeks, the RCT phase. Researchers will compare 120mg methylprednisolone with 40mg methylprednisolone and placebo to see if there is a difference in hand pain after 4 weeks.\n\nParticipants will be asked to visit the hospital for:\n\n* injection of the study material\n* ultrasound assessment\n* physical examination like joint assessments and grip strenght\n* examination of blood\n* x-ray of the hand\n\nIn phase 2, from week 16 to 48, an open label phase focusing on treatment strategy and safety. In this phase all participants may receive intramuscular methylprednisolone on demand at the dosage of 120mg only if they fulfil the following conditions: hand pain \\> 30mm on a VAS (0-100mm) and a minimum of 16 weeks interval between two consecutive injections. Therefore, a maximum of two injections could be received during this period. Irrespective of that, all participants will be followed-up until week 48 when the end-of-study visit will take place.",[27],"2026-01-19",{"date":63,"type":38},"2026-01-28",{"date":65,"type":38},"2025-10-28",{"date":67,"type":21},"2028-11",{"name":69,"class":45},"Sint Maartenskliniek",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100335688","a-prospective-cohort-study-of-patients-suffering-from-hand-osteoarthritis-symptoms-100335688","NCT03650673","A Prospective Cohort Study of Patients Suffering From Hand Osteoarthritis Symptoms","A Prospective Cohort Study of Patients Suffering From Hand Osteoarthritis","COARDIG","Inclusion Criteria:\n\n\\- Early digital osteoarthritis must combine the clinical AND radiological definition.\n\nClinical definition:\n\nAt least one of the following 4 criteria: Pain or stiffness or swelling or deformity of a digital joint (IPP and \u002F or IPD) A breach of at least one PPI and \u002F or IPD Age under 60 at the time of the first symptoms Clinical symptoms have been changing for less than 3 years\n\nRadiographic definition:\n\nThe presence of the achievement of at least one PPI and \u002F or IPD. Presence of at least two of the following three criteria: pinching, marginal subchondral condensation, marginal osteophyte Erosion on radiography is not an exclusion criteria\n\n\\- Consent form signed\n\nExclusion criteria:\n\n* patients suffering from rheumatoid arthritis, rheumatoid psoriasis or any other inflammatory rheumatism\n* patients suffering from metabolic diseasis such as gout, hemochromatosis, Wilson's disease; or from congenital disease such as displasie, osteogenesis,\n* Presence of advanced radiographic osteoarthritis based in Kellgreen Lawrence score (=4) in one joint among the 10 previous sites.\n* Not able to provide a sample of blood for any reasons\n* MRI contraindication\n* Being in exclusion period determined by another previous study\n* Subject non affiliated to social insurance\n* Pregnant or lactating women\n* Vulnerable people based in L1121-5 article of CSP\n* Elderly subject or protected subjects disabled to give their consent\n* Subjects private of freedom by court or administrative order","60 Years",{"count":80,"type":21},150,[82],"NA","The late-stage forms of degenerative osteoarthritis (OA) are very debilitating and less affordable to therapy. The main objective is to identify early onset symptoms of hand OA patients through imaging techniques (such as ultrasound and MRI). Our primary endpoint is to specify patients with high risk of radiological profression (X-ray).",[27],[86,87,88,89],"Hand osteoarthritis","Prospective cohort","Cartilage","Mobility","2025-09-24",{"date":92,"type":38},"2025-09-30",{"date":94,"type":38},"2019-07-15",{"date":96,"type":21},"2028-10-31",{"name":98,"class":45},"University Hospital, Montpellier",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":46},"100459782","acupuncture-vs-sham-acupuncture-for-hand-osteoarthritis-100459782","NCT05267093","Acupuncture vs Sham Acupuncture for Hand Osteoarthritis","Efficacy of Acupuncture for Patients With Hand Osteoarthritis: a Randomized, Sham-controlled Trial","Inclusion Criteria:\n\n* Diagnosed as hand OA according to the American College of Rheumatology (ACR) clinical classification criteria\n* History of hand OA for at least 3 months before enrollment and history of taking nonsteroidal anti-inflammatory drugs (NSAIDs) to treat hand OA\n* Aged 18-80 years\n* At least 40 mm in visual analog scale (VAS) on the average pain intensity of the dominant hand over the last 48 hours (patients applying NSAIDs at the screening have to have an increase in pain in the dominant hand of ≥ 20 mm after 1-week washout)\n* Posterior-anterior radiographs of the dominant hand shows Kellgren-Lawrence grade 1, 2, or 3 changes in symptomatic joints\n* Negative results in both rheumatoid factor and anticyclonic citrullinated peptide\n* Able to comply with the study protocol and understand the medical information forms\n* Voluntarily sign the informed consent\n\nExclusion Criteria:\n\n* History or current evidence of secondary OA (due to causes other than a solely degenerative joint disease) or symptomatic OA at additional locations besides the hand(s) requiring treatment, or any painful syndrome of the upper limb which may interfere with evaluation of hand pain;\n* History of inflammatory arthritis (such as rheumatoid arthritis (RA) or psoriatic arthritis), hemochromatosis, metabolic, or neuropathic arthropathies;\n* History of trauma, dislocation or operation to the hand or arm in the previous 3 months;\n* Hand pain and stiffness due to tissue scarring or tendinitis;\n* Skin damage or serious skin disorders in the hands;\n* Intake of antidepressants, anticonvulsants, vascular or narcotics during the 10 days prior to beginning the study;\n* Oral, intramuscular, intra-articular or intravenous corticosteroids, or hyaluronic acid injection within 3 months preceding enrollment;\n* Serious uncontrolled medical conditions such as cancer, uncontrolled cardiovascular disorder, severe hepatic\u002Frenal insufficiency or coagulation disorder;\n* Known phobic to acupuncture or received acupuncture treatment within 4 weeks prior to enrollment.","80 Years",{"count":108,"type":21},340,[82],"The investigators plan to conduct this multicentered, sham-controlled randomized clinical trial to evaluate the efficacy and safety of acupuncture for clinical symptomatic improvement of hand OA.",[27],"2025-07-13",{"date":114,"type":38},"2025-07-16",{"date":116,"type":38},"2022-04-26",{"date":118,"type":21},"2026-12",{"name":120,"class":45},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":46},"100590111","testing-of-a-new-joint-protection-program-100590111","NCT06963164","Testing of a New Joint Protection Program","Feasibility of a Remotely-Delivered, Technology-Enabled, Joint Protection Program","\"Helping Hand\"","Inclusion Criteria:\n\nDiagnosis of hand osteoarthritis Pain symptoms for at least 3 months Ability to use a smartphone, tablet, or computer Ability to communicate in English\n\nExclusion Criteria:\n\nPresence of neurological disorders, dementia, or other cognitive conditions that could interfere with trial procedures Scheduled hand surgery within the next 3 months",{"count":130,"type":21},60,[82],"The goal of this study is to to examine the feasibility of a full-scale trial on Helping Hand, a new Joint Protection Program for Hand Osteoarthritis and to examine the acceptability of the new Joint Protection Program.\n\nThis study will not assess the effectiveness of the program, as it is not designed or powered to do so. Instead, the information gathered will be used to refine the trial design and ensure the future full-scale trial that will assess the effectiveness of the program is robust and successful. The acceptability of the new Joint Protection Program will be assessed through a survey that will be administered to the intervention group at the end of the trial, which will be based on a standardized acceptability framework\n\nParticipants will:\n\nGain access to an online Joint Protection Program or continue to receive usual care for 12 weeks Visit the clinic or complete online assessments once every 4 weeks Keep a diary of their symptoms and the number of times they used other interventions to manage their symptoms (i.e. painkillers)",[27],[29,135,136,137],"randomize controlled trial","feasibility","pilot","NOT_YET_RECRUITING","2025-04-29",{"date":141,"type":38},"2025-05-08",{"date":143,"type":21},"2025-09",{"date":145,"type":21},"2026-06",{"name":147,"class":45},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":46},"100544315","phase-3-metformin-treatment-of-patients-with-hand-osteoarthritis-100544315","NCT06367283","Metformin Treatment of Patients with Hand Osteoarthritis","Metformin Treatment of Patients with Hand Osteoarthritis: a Randomised, Placebo-controlled Trial","METRO","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hand OA according to the ACR criteria\n3. Average finger (2 to 5) pain ≥4 on a 0-10 numeric rating scale (NRS where 10 is worst pain) over the past 30 days\n4. Metformin naive\n\nExclusion Criteria:\n\nComorbidities\n\n1. History of, or current signs of medical disease that may affect joints, e.g. rheumatoid arthritis, gout, psoriatic arthritis\n2. Psoriasis\n3. Known malignancy (except successfully treated squamous or basal cell skin carcinoma)\n4. Drug or alcohol abuse in the last year\n5. Existing nerve entrapment syndromes (e.g. carpal tunnel syndrome)\n6. Known diabetes\n7. Generalised pain syndromes such as fibromyalgia\n8. Known peripheral neuropathies\n9. Known allergies towards the interventions\n10. Gastric bypass or other malabsorption syndrome\n11. In case of pharmacological weight loss medication (e.g. glucagon like peptide-1 (GLP-1) analogues) or pharmacological osteoporosis medication, dosage must have been stable for 3 months without any plan of up-titration during the study period\n12. Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or obstructs participation e.g. psychiatric disorders.\n\n    Surgical history\n13. History of hand surgery in the target hand within 12 months prior to enrolment\n14. History of arthroplasty, arthrodesis or surgical treatment of thumb base osteoarthritis in the target hand\n\n    Management strategies\n15. Use of systemic corticosteroids equivalent of ≥ 7.5 mg prednisolone daily within 3 months\n16. Treatment with denosumab (Prolia\u002FXgeva)\n17. Participation in experimental device or experimental drug study 3 months prior to enrolment\n18. Intra-articular treatments of any kind of any joint of the target hand 3 months before inclusion\n19. Current use of synthetic or non-synthetic opioids\n20. Planning to start other treatment for hand OA in the study participation period\n21. Planned CT scan with iodine contrast\n22. Scheduled surgery on upper extremity of the target hand during study participation\n23. Scheduled surgery requiring pause of metformin, e.g. surgery in general anaesthesia, during study participation\n\n    Reproductive system\n24. Pregnancy\n25. Planned pregnancy within the study period, 3 months after end of study treatment for female fertile participant and 6 months after end of study treatment for male participant\n26. Insufficient anti-conception therapy for female fertile participants within the study period and 3 months after end of study treatment\n\n    * Sufficient anti-conception therapy consists of intra-uterine device (coil), hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections) or sexual abstinence\n    * Female participants are considered infertile if they are postmenopausal or if they have undergone surgical sterilisation (bilateral salpingectomy, hysterectomy or bilateral oophorectomy)\n    * Postmenopausal state is defined as no menses for 12 months without alternative medical cause before inclusion in the study\n27. Insufficient anti-conception therapy for male participants within the study period and 6 months after end of study treatment\n\n    * Sufficient anti-conception therapy consists of condom or sexual abstinence\n    * Male participants are considered sterile if they have undergone surgical sterilisation (vasectomy)\n28. Breast-feeding\n\n    Blood analysis\n29. Positive anti-cyclic citrullinated peptide (\\>10 kU\u002FL)\n30. eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m2\n31. Vitamin B12 deficiency \\\u003C 200 pmol\u002FL\n32. Hba1c ≥ 48 mmol\u002Fmol",{"count":80,"type":21},[24],"To compare metformin (2 g daily), or maximum tolerated dose, for 16 weeks with placebo as a treatment of hand osteoarthritis symptoms.",[27],"2025-02-25",{"date":162,"type":38},"2025-02-27",{"date":164,"type":38},"2024-06-03",{"date":166,"type":21},"2026-04",{"name":168,"class":45},"Marius Henriksen",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":46},"100577156","cross-sectorial-management-program-for-people-living-with-hand-osteoarthritis-a-randomised-controlled-pilot-and-feasibility-study-100577156","NCT06794632","Cross-sectorial Management Program for People Living with Hand Osteoarthritis: a Randomised Controlled Pilot and Feasibility Study","A Protocol for a Randomised Controlled Pilot and Feasibility Study","HANDY","Inclusion Criteria:\n\n* People diagnosed by general practitioner with hand osteoarthritis\n* Aged \\> 18 years\n* Experiencing decreased ADL ability\n\nExclusion Criteria:\n\n* Severe vision loss\n* Severe hearing loss\n* Cognitive deficits affecting the ability to engage in peer-learning activities\n* Unable to participate in two or more group sessions due to other scheduled activities (e.g. holidays\u002Ftravels).\n* Acute illness is the primary reason for decreased ADL ability (Will be referred to other services in the municipality).",{"count":178,"type":21},32,[82],"To investigate the research design (pilot-RCT) and feasibility of the HANDY program for people with hand osteoarthritis (version 2.0). In collaboration with two municipalities (Lyngby-Taarbæk and Ballerup), the research design is tested in a pilot-RCT before planning a full-scale RCT study. The entire HANDY program is described in a manual, which has been adjusted to version 2.0 based on a previous feasibility study. The focus of the study will be on procedures related to recruitment and retention, the study's acceptance in practice, and the appropriateness of assessment tools in connection with the occupational therapy group intervention. The feasibility and acceptance of the HANDY program version 2.0 are also examined in this study.",[27],[86,183,184],"Activity of Daily Living","Group intervention","2025-01-21",{"date":187,"type":38},"2025-01-27",{"date":189,"type":38},"2025-01-13",{"date":191,"type":21},"2025-06-30",{"name":193,"class":45},"Parker Research Institute",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100570074","balneotherapy-in-hand-osteoarthritis-100570074","NCT06702514","Balneotherapy in Hand Osteoarthritis","Effectiveness of Balneotherapy in the Treatment of Hand Osteoarthritis: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Between the ages of 50-75\n* Hand osteoarthritis diagnosed according to ACR criteria\n\nExclusion Criteria:\n\n* Non-cooperative patients\n* Trauma or surgery to the hand region in the last 6 months\n* Infection\n* Infection, loss of sensation, metal implant in the treatment area\n* Injection to the hand joints in the last 3 months\n* Physical therapy and rehabilitation to the hand region in the last 3 months\n* Balneotherapy in the last 3 months\n* Inflammatory rheumatic diseases\n* NSAI use\n* Planning pregnancy during pregnancy or treatment\n* Malignancy\n* Presence of a neurological disease\n* Hand-wrist entrapment neuropathy\n* Loss of muscle strength or sensation in the hand\n* Uncontrolled cardiopulmonary disease\n* Open wound\n* Orthopedic condition that would prevent entering the spa","50 Years","75 Years",{"count":204,"type":21},50,[82],"There are a limited number of studies in the literature on the effectiveness of balneotherapy in hand osteoarthritis. The aim of this study was to evaluate the effects of balneotherapy on pain, manual skills, functionality and quality of life in patients with hand osteoarthritis who have undergone balneotherapy.",[27],"2024-11-21",{"date":210,"type":38},"2024-11-25",{"date":212,"type":21},"2024-12-15",{"date":214,"type":21},"2025-12-15",{"name":216,"class":45},"Afyonkarahisar Health Sciences University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":225,"maxAge":106,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100536444","an-integrated-self-management-programme-to-improve-outcomes-in-patients-with-hand-osteoarthritis-100536444","NCT06264908","An Integrated Self Management Programme to Improve Outcomes in Patients With Hand Osteoarthritis","Hand OsteoArthritis Self-management and Integrated Scheme (OASIS-H) to Improve Outcomes in Patients With Hand Osteoarthritis","OASIS-H","Inclusion Criteria:\n\n* Fulfil the American College of Rheumatology hand osteoarthritis classification criteria\n* Symptomatic hand osteoarthritis with a pain visual analogue score (VAS) equal to or more than 40\u002F100mm within 2 weeks of study entry\n\nExclusion Criteria:\n\n* Secondary hand osteoarthritis from inflammatory arthritis including rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, gouty arthropathy or connective tissue diseases;\n* Receive systemic corticosteroids (other than topical or inhalational) within 6 months of study entry\n* Inability to sign informed consent","40 Years",{"count":227,"type":21},90,[82],"The goal of this trial is to evaluate the efficacy of an integrated self-management programme in improving clinical outcomes in patients with hand osteoarthritis (OA).\n\nThis is an open-labelled, randomized controlled trial with an objective to determine the efficacy of an integrated self-management programme versus routine clinical care for participants with symptomatic hand OA.\n\nParticipants will be randomized into early intervention group and routine clinical care groups in a 1:1 ratio. Patients who randomized into early intervention group will receive 8 week integrated self-management programme delivered by occupational therapists and rheumatology nurse on hand OA management. Patients who randomized into routine clinical care group will receive usual clinical care for OA for 26 weeks and then receive an identical 8 weeks integrated self-management programme. The primary outcome is the improvement in pain at 26 weeks between the two groups.",[27],[29,232],"self-management programme","2024-02-14",{"date":235,"type":38},"2024-02-20",{"date":237,"type":21},"2024-04",{"date":239,"type":21},"2028-04",{"name":241,"class":45},"Dr Iris Tang Yan Ki"]